ECMO without Anticoagulation

无抗凝的 ECMO

基本信息

批准号：
10876766
负责人：
Alvaro Rojas-Pena
金额：
$ 8.59万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10876766
关键词：
Accounting Adhesions Affect Animal Model Anticoagulants Anticoagulation Argatroban Attention Binding Blood Platelets Blood flow Cardiopulmonary Bypass Chemistry Clinical Trials Coagulation Process Critical Care Development Devices Dose Effectiveness Endothelium Experimental Designs Extracorporeal Circulation Fibrin Functional disorder Gases Generations Goals Grant Heart failure Hemodialysis Hemofiltration Hemorrhage Heparin Hour Incidence Laboratories Learning Life Medicine Membrane Oxygenators Morbidity - disease rate Nitric Oxide Oxygenators Patients Platelet Activation Research Research Project Grants Risk SARS-CoV-2 infection Series Sheep Source Standardization Surface System Technology Testing Thrombin Thrombosis Time United States National Institutes of Health commercial application compare effectiveness comparison control design effectiveness evaluation experimental study hydrophilicity inhibitor lung failure mortality platelet function pre-clinical prevent prototype surface coating thrombogenesis

项目摘要

PROJECT SUMMARY/ABSTRACT Life support with extracorporeal circulation through a membrane oxygenator (ECMO) is a mainstay of advanced critical care. However, clotting in the ECMO circuit and bleeding from the patient are the major complications, accounting for morbidity and mortality in 30% of patients. Surface–based coatings are available, but still require systemic anticoagulation because these surfaces do not prevent platelet adhesion and activation. We have developed a nonthrombogenic surface which prevents platelet activation at the surface. This could eliminate the need for systemic anticoagulation and prevent major bleeding and circuit clotting complications. The surface is based on nitric oxide (NO), which is the mechanism of surface anticoagulation of the normal endothelium. The chemistry, coating, NO generation, and effectiveness have been tested in preliminary studies. This research will refine the nitric oxide surface anticoagulation system (NOSA), and demonstrate effectiveness compared to systemic anticoagulation. The results will apply to nonthrombogenic surfaces for other extracorporeal devices such as hemodialysis, hemofiltration, and cardiopulmonary bypass.

项目摘要/摘要通过膜氧合（ECMO）的体外循环的生命支持是高级重症监护的支柱。但是，在ECMO电路中关闭并从患者是主要的并发症，这是30％的患者的发病率和死亡率。提供基于表面的涂料，但仍然需要全身抗凝治疗，因为这些表面不能防止血小板粘附和激活。我们已经开发了非单畅的表面可防止表面血小板激活。这可能会消除对全身性抗凝并防止重大出血和电路衣服并发症。这表面基于一氧化氮（NO），这是表面抗凝的机理正常内皮。已经测试了化学，涂层，没有发电和有效性在初步研究中。这项研究将完善一氧化氮表面抗凝系统（NOSA），并且与全身抗凝作用相比表现出有效性。结果将应用于其他体外设备，例如血液透析，血液滤过和心肺旁路。